ClinicalTrials.gg
RecruitingNCT07556523Updated Apr 29, 2026

Patient Quality of Recovery After TAVR With Different Sedation Regimens

A Phase 4 interventional study of Propofol and Dexmedetomidine in Transcatheter Aortic Valve Replacement (TAVR) and Aortic Valve Stenosis, sponsored by David Lyubashevsky. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by David Lyubashevsky · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Aortic Valve Stenosis with a site in United States — 43 open to participants now, 67 under way, 3 of them phase 3. Aortic Valve Stenosis · United States.

Planned enrollment
65th of 125
126 · median 172
Started
2026
with 9 others
Phase 4
6 of 189
1 open now
Primary completion
2028-04
later than 46 of 66 live
Registered
186th of 189
by date

Among the 189 studies in Aortic Valve Stenosis with a site in United States, this one is the 65th largest by planned enrollment of the 125 interventional ones that give a count, is one of 10 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 46 of the 66 other live ones, and was the 186th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 189 studies in Aortic Valve Stenosis with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Aortic Valve Stenosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether the type of sedation medication used during a transcatheter aortic valve replacement (TAVR) affects how people recover after the procedure. The main question this study aims to answer is whether different sedation regimens (propofol, dexmedetomidine, or midazolam with fentanyl) lead to differences in quality of recovery on the first day after the procedure.

Researchers will compare three commonly used sedation medications (propofol, dexmedetomidine, or midazolam with fentanyl) to determine whether they lead to differences in recovery following a TAVR.

Participants will:

  • Be enrolled before their scheduled TAVR procedure
  • Be randomly assigned to receive one of the three sedation medications during their procedure
  • Complete short surveys on postoperative days 1 and 7 about pain levels, how they feel during their recovery, and how satisfied they were with their anesthesia experience
03

Conditions studied

  • Transcatheter Aortic Valve Replacement (TAVR)
  • Aortic Valve Stenosis

Keywords

  • Transcatheter aortic valve replacement
  • TAVR
  • Sedation strategy
  • Anesthesia
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-90 years old, inclusive
  • Undergoing transfemoral TAVR under Monitored Anesthesia Care (MAC)
  • Speaks English or Spanish
  • Consents to participate

Exclusion criteria

Exclusion Criteria:

  • Preoperative heart rate \< 50 bpm or arrhythmias (e.g., AFib with RVR)
  • Conduction abnormalities (e.g., 2nd/3rd degree AV block without pacer)
  • Allergy or to study drugs
  • Pulmonary artery pressure > 70mmHg
  • Morbid obesity > 50
  • Pregnancy
  • Unable to consent in English or Spanish
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Propofol

    Participants will receive propofol for intraoperative sedation during transcatheter aortic valve replacement (TAVR).

    Drug: Propofol

  • Experimental
    Dexmedetomidine

    Participants will receive dexmedetomidine for intraoperative sedation during transcatheter aortic valve replacement (TAVR).

    Drug: Dexmedetomidine

  • Experimental
    Midazolam and Fentanyl

    Participants will receive a combination of midazolam and fentanyl for intraoperative sedation during transcatheter aortic valve replacement (TAVR).

    Drug: Midazolam · Drug: Fentanyl

Interventions

  • Propofol will be administered intravenously for intraoperative sedation during transcatheter aortic valve replacement (TAVR), with initiation and maintenance infusion dosing of 5-100 mcg/kg/min, titrated to clinical effect according to standard anesthesia practice.

  • Dexmedetomidine will be administered intravenously for intraoperative sedation during transcatheter aortic valve replacement (TAVR), with initiation and maintenance infusion dosing of 0.2-1.0 mcg/kg/hr, titrated to clinical effect according to standard anesthesia practice.

  • Midazolam will be administered intravenously for intraoperative sedation during TAVR and titrated to achieve adequate sedation and analgesia according to standard anesthesia practice.

  • Fentanyl will be administered intravenously for intraoperative sedation during TAVR and titrated to achieve adequate sedation and analgesia according to standard anesthesia practice.

06

What researchers measure

Primary outcomes

  1. Quality of Recovery on Postoperative Day 1 Measured by QoR-15 Survey

    The primary outcome of the study will be the quality of recovery, as measured by the Quality of Recovery-15 (QoR-15) score. A baseline QoR-15 survey will be taken before or on the day of the procedure, and the resulting aggregate score will be compared to the score from the QoR-15 survey completed on post-operative day 1 (POD 1). The QoR-15 survey is 15-item questionnaire which has a scale of 0-10 pertaining to a patient's comfort, support system, pain, well-being, and ability to carry out daily activities. For questions 1-10, number "0" indicates none of the time and number "10" indicates all of the time. For questions 11-15, number "0" indicates all of the time and number "10" indicates none of the time. A higher overall score indicates a better outcome (i.e. better quality of recovery) and a lower score indicates a worse outcome (i.e. poorer quality of recovery).

    Time frame: From baseline assessment prior to transcatheter aortic valve replacement (TAVR) through postoperative day 1

Secondary outcomes

  1. Heart Rate Change

    Change in heart rate from baseline to nadir intraoperatively and at Post-Anesthesia Care Unit (PACU) admission.

    Time frame: Intraoperative period through PACU admission

  2. Length of Stay

    PACU length of stay and total hospital length of stay

    Time frame: From date of procedure through hospital discharge (up to 30 days after procedure date, whichever comes first)

  3. Patient Satisfaction with Anesthesia Measured by 5-Point Likert Scale

    Patient-reported satisfaction with anesthesia measured using a 5-point Likert scale. Patients will respond to this statement: The anesthesia care I received during my transcatheter aortic valve replacement (TAVR) procedure met my expectations (5 = Strongly Agree; 1 = Strongly Disagree).

    Time frame: Postoperative day 1 and postoperative day 7

  4. Pain Scores Measured by Visual Analog Scale (VAS)

    Pain severity measured using the Visual Analog Scale (VAS).

    Time frame: Upon post-anesthesia care unit (PACU) arrival (within ~2 hours after procedure), upon PACU discharge (~4 hours after procedure/medically cleared to leave PACU), on postoperative day 1, and postoperative day 7

  5. Quality of Recovery on Postoperative Day 7 Measured by QoR-15 Survey

    Quality of recovery measured using the Quality of Recover-15 (QoR-15) questionnaire on postoperative day 7. The QoR-15 survey is 15-item questionnaire which has a scale of 0-10 pertaining to a patient's comfort, support system, pain, well-being, and ability to carry out daily activities. For questions 1-10, number "0" indicates none of the time and number "10" indicates all of the time. For questions 11-15, number "0" indicates all of the time and number "10" indicates none of the time. A higher overall score indicates a better outcome (i.e. better quality of recovery) and a lower score indicates a worse outcome (i.e. poorer quality of recovery).

    Time frame: Postoperative day 7

  6. Cardiologist Operating Conditions Rating

    Cardiologist-rated procedural conditions assessed using a 5-point Likert scale. The cardiologist will report their satisfaction with the TAVR patient's surgical condition (5 = Very Satisfied; 1 = Very Dissatisfied)

    Time frame: Immediately after completion of the TAVR procedure (intraoperative period)

  7. 30-Day Readmission Rates

    Hospital readmission rates within 30 days following TAVR

    Time frame: Within 30 days post-hospital discharge.

  8. Incidence of Hypotension Requiring Medical Intervention

    Incidence of hypotension (defined as ≥20% reduction from baseline) requiring medical intervention.

    Time frame: Intraoperative period

  9. Fluid Administration From Start of Procedure Through PACU Discharge

    Total intravenous fluid volume administered.

    Time frame: From procedure start through post-anesthesia care unit discharge (~4 hours after procedure/medically cleared to leave PACU)

  10. Incidence of Intraoperative Bradycardia

    Incidence of heart rate \< 60 beats per minute.

    Time frame: Intraoperative period

  11. Surgical Bleeding

    Incidence of clinically significant surgical bleeding.

    Time frame: Intraoperative period

  12. Conversion to General Anesthesia

    Need for conversion from planned sedation to general anesthesia.

    Time frame: Intraoperative period

  13. Postoperative Pacemaker Placement

    Need for new permanent pacemaker implantation after TAVR.

    Time frame: During postoperative period (within 30 days)

  14. Postoperative Delirium Measured by 4AT Assessment

    Incidence of postoperative delirium assessed using the 4AT screening tool.

    Time frame: Preoperative baseline, upon PACU discharge (~4 hours after procedure/medically cleared to leave PACU), and 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to institutional policies and to protect participant privacy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2028, 25 months after the start.

Of 25 phase 4 interventional studies under Aortic Valve Stenosis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 29, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Jun 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556523
Lead sponsor
David Lyubashevsky
Responsible party
David Lyubashevsky (Anesthesiologist, Endeavor Health) — Sponsor-investigator
First posted
Apr 29, 2026
Start date
Mar 16, 2026
Primary completion
Apr 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Jessica Brickner
Contact
jessica.brickner@endeavorhealth.org
847-570-1197
Nia Moragne
Contact
nia.moragne@endeavorhealth.org
847-570-1197

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Propofol · Dexmedetomidine · Midazolam · Fentanyl

Start the discussion